Statistics in Biopharmaceutical Research

Papers
(The H4-Index of Statistics in Biopharmaceutical Research is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)
ArticleCitations
U-MET: Utility-Based Dose Optimization Approach for Multiple-Dose Randomized Trial Designs42
Treatment Selection at Interim Analysis Based on a Correlated Early Endpoint in Adaptive Two-Stage Trials with a Primary Endpoint Based on Count Data26
DODII: Bayesian Dose Optimization Design for Randomized Phase II Trials20
Predicting Probability of Success for Phase III Trials via Propensity-Score-Based External Data Borrowing18
A Landscape Assessment of Key Evidence Needs in Study Design and Statistical Methodologies for HTA Submissions17
Consistency Based Multiplicity Adjustment Approach—Multiple Doses in Phase III Studies16
Considerations on Interim Evaluation of OS in Pivotal Oncology Trials16
Some Multiplicity Adjustment Procedures for Clinical Trials with Sequential Design and Multiple Endpoints14
Missing Data Imputation for a Multivariate Outcome of Mixed Variable Types13
Bayesian and Frequentist Approaches to Rescuing Disrupted Trials: A Report from the NISS Ingram Olkin Forum Series on Unplanned Clinical Trial Disruptions12
The Current Landscape of HTA Framework and Key Challenges12
Modified Simon’s Two-Stage Design for Phase IIA Clinical Trials in Oncology—Dynamic Monitoring and More Flexibility11
1.4380149841309